Remdesivir
- PDF / 169,410 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 65 Downloads / 187 Views
1 S
Remdesivir Intrahepatic cholestasis of pregnancy following compassionate use of remdesivir: case report
In a case series of 3 patients, a 25-year-old woman was described, who developed intrahepatic cholestasis of pregnancy (IHCP) following compassionate use of remdesivir for COVID-19. The woman presented with fever, tachycardia, and tachyponea at 34 weeks of gestation. After investigations, she was diagnosed with COVID-19. On hospital day 2, she was transferred to the ICU for increasing oxygen requirement on nasal cannula. She started receiving IV remdesivir at single loading dose of 200mg, followed by IV remdesivir 100mg daily from day 2. She received total of 3 doses of remdesivir. However, she developed transaminitis [time to reaction onset not stated]. She was diagnosed with IHCP in the setting of markedly increased levels of bile acids. Thus, woman’s additional doses of remdesivir were withheld. On day 8, she was discharged. Later, she had an uncomplicated vaginal delivery following scheduled induction at 37 weeks and 2 days of gestation due to IHCP [ADR outcome not stated]. Igbinosa I, et al. Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019. American Journal of Obstetrics and Gynecology 223: 768-770, No. 5, 803518386 Nov 2020. Available from: URL: http://doi.org/10.1016/j.ajog.2020.08.001
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
